Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma

Journal of Allergy and Clinical Immunology

Volumn 103, Issue 6, 1999, Pages 1075-1080

  Busse, William ^a,e   Nelson, Harold ^b   Wolfe, James ^c   Kalberg, Christopher ^d   Yancey, Steven W ^d   Rickard, Kathleen A ^d  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^c Allergy & Asthma Associates of Northern California   (United States)

^d GLAXOSMITHKLINE   (United States)

^e UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Asthma; Leukotriene receptor antagonist; Peak expiratory flow; Salmeterol xinafoate; Zafirlukast; 2 agonist

Indexed keywords

SALBUTAMOL; SALMETEROL; SALMETEROL XINAFOATE; ZAFIRLUKAST;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTHMA; CLINICAL TRIAL; COMMON COLD; COMPARATIVE STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; INHALATION; INHALATIONAL DRUG ADMINISTRATION; MALE; MULTICENTER STUDY; NERVOUSNESS; ORAL DRUG ADMINISTRATION; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; RELAPSE; SCHOOL CHILD; SLEEP; WAKEFULNESS;

EID: 0032864563     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-6749(99)70182-X     Document Type: Article

References (20)

1. 1. National Heart, Lung, and Blood Institute. Expert Panel Report 2: guidelines for the diagnosis and management of asthma. Bethesda (MD): National Institutes of Health; April 1997. Publication no. 97-4051.
2. 2. Spector SL, Smith LJ, Glass M. Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group. Am J Respir Crit Care Med 1994;150:618-23.
3. 3. Fish JE, Kemp JP, Lockey RF, et al. Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study. Clin Ther 1997;19:675-90.
4. 4. Suissa S, Dennis R, Ernst P, Sheehy O, Wood-Dauphine S. Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma. Ann Intern Med 1997;126:177-83.
5. 5. Dahl R, Earnshaw JS, Palmer JBD. Salmeterol: a four week study of a long-acting beta-adrenoreceptor agonist for the treatment of reversible airways disease. Eur Respir J 1991;4:1178-84.
6. 6. Britton MG, Earnshaw JS, Palmer JBD. A twelve month comparison of salmeterol with salbutamol in asthmatic patients. Eur Respir J 1992;5:1062-7.
7. 2-agonist salmeterol compared with albuterol in maintenance asthma therapy. Ann Allergy Asthma Immunol 1995;75:180-4.
8. 8. Bateman ED, Aitchison JA, Summerton L, Harris A. The early onset of action of zafirlukast (Accolate™ in patients with asthma [abstract]. Am J Respir Crit Care Med 1997;155:A663.
9. 9. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease and asthma. Am Rev Respir Dis 1987;136:225-44.
10. 10. Crapo RO, Morris AH, Gardner RM. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis 1981;123:659-64.
11. 11. Polgar G, Promadhat V. Pulmonary function testing in children: techniques and standards. Philadelphia: WB Saunders; 1971.
12. 12. American Thoracic Society. Lung function testing: selection of reference values and interpretative strategies. Am Rev Respir Dis 1991;144:1202-8.
13. 13. Hay DW, Torphy TJ, Undem BJ. Cysteinyl leukotrienes in asthma: old mediators up to new tricks. Trends Pharmacol Sci 1995;16:304-9.
14. 14. Henderson WR Jr. The role of leukotrienes in inflammation. Ann Intern Med 1994;121:684-97.
15. 15. Rodger IW. Role of leukotrienes and leukotriene receptor antagonists in asthma: new advances. J Investig Allergol Clin Immunol 1997;7:279.
16. 16. Spector SL. Leukotriene activity modulation in asthma. Drugs 1997;54:369-84.
17. 17. Singulair (montelukast sodium) package insert. West Point (PA): Merck & Co, Inc; 1998.
18. 18. Butchers PR, Vardey CJ, Johnson M. Salmeterol: a potent and long-acting inhibitor of inflammatory mediator release from human lung. Br J Pharmacol 1991;104:672-6.
19. 19. Meyer JM, Wenzel CL, Kradjan WA. Salmeterol: a novel, long-acting β2-agonist. Ann Pharmacother 1993;27:1478-87.
20. 20. Johnson M. Pharmacology of long-acting β-agonists. Ann Allergy Asthma Immunol 1995;75:177-9.